QualityStocksNewsBreaks Archives - Page 703 of 1390

ThursdayMar 18, 2021 10:36 am

QualityStocksNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Launches Probulin Probiotics in China Through World’s Largest Cross-Border Marketplace

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, through its wholly owned subsidiary Probulin Probiotics LLC, is offering products in China. The products are available on Alibaba Group Holding’s Tmall (“Tmall”) Global, the world’s largest cross-border online marketplace, with a reach of more than 750 million potential customers in China, Hong Kong, Macau and Taiwan. Calling the move a tremendous opportunity, the company plans to begin shipping product next week, with products available for purchase beginning March 29, 2021. The company anticipates having its Total Care…

ThursdayMar 18, 2021 10:25 am

QualityStocksNewsBreaks – The Movie Studio Inc. (MVES) Leverages Blockchain for Licensing of ‘Night of the Demons’ in Spain

The Movie Studio (OTC: MVES), a vertically integrated motion picture production and distribution company with completed motion picture and production assets, today announced the licensing of its 60%-owned membership of the motion picture “Night of the Demons,” starring Shannon Elizabeth, Edward Furlong and Monika Keena, for the territory of Spain, which has a combined population of 47 million. According to the update, the licensing will remain in effect through 2027. “Establishing worldwide distribution agreements for our current library of new and aggregated revenue-shared titles through our blockchain application is a fundamental cornerstone of our proposed reverse engineering of future revenue-share…

ThursdayMar 18, 2021 10:01 am

QualityStocksNewsBreaks – Net Element Inc. (NASDAQ: NETE), Mullen Set to Move the World in Memphis

Net Element (NASDAQ: NETE) is in the process of transforming its business model to become a pure-play electric vehicle ("EV") manufacturer through a pending stock-for-stock reverse merger with privately-held Mullen Technologies Inc. Mullen today announced its intent to execute a long-term lease on an 820,000-square-foot facility located in Memphis, Tennessee. According to the update, Mullen, with the help of local and state incentives from the city of Memphis and the state of Tennessee, plans to create up to 800 jobs and deliver 100,000 vehicles over a five-year period, commencing in Q4 of 2023. Mullen’s 2P 6 SUV crossover (formerly MX-05)…

ThursdayMar 18, 2021 9:50 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Receives European Approval for 25 Minute COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH ("3a"), has received European approval of its point-of-care SARS-CoV-2 RT-PCR test system, called Covid-ID Lab. Covid-ID Lab is now registered as a commercial in vitro diagnostic (CE-IVD) test in Europe, and plans are in place to launch the product in Europe in April 2021. XPhyto is exploring options with various potential distribution and wholesale partners as well as potential licensees. The test offers high sensitivity, high specificity, and high robustness,…

WednesdayMar 17, 2021 2:56 pm

QualityStocksNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces Filing of Reg A with the SEC

Healthtech Solutions (OTC: HLTT), parent company of Medi-Scan Inc. and RevHeart Inc., today announced that it filed a Reg A with the Securities and Exchange Commission on Monday, March 8, 2021, to raise up to $75 million. According to the update, the company is offering up to a maximum of 1,500,000 shares of Series B preferred stock, $0.001 par value (“Preferred Stock”), at an offering price of $50 per share. The price will remain fixed for the duration of the Offering (the “Offered Shares”). The Offering will enable Healthtech Solutions to implement its three-pronged growth plan, which includes: the creation…

WednesdayMar 17, 2021 2:31 pm

QualityStocksNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Announces Completion of Uranium Purchases, Additional Funding

Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company, has secured 800,000 pounds of additional U.S.-warehoused uranium; the shipment is comprised of a delivery in April consisting of 500,000 pounds and a second delivery scheduled for December consisting of 300,000 pounds; this uranium purchase follows a previously announced acquisition of 400,000 pounds. In total, UEC now has contracts to purchase 1,200,000 pounds of U3O8 at a volume-weighted average price of $28.94 per pound. In addition, the company has entered into definitive agreements with institutional investors to purchase 10,000,000 UEC common shares at $3.05 per share. The registered direct offering, which…

WednesdayMar 17, 2021 1:22 pm

QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In addition, two to three more clinical sites will be selected for the trial, “A Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica.” “We have selected five U.S. sites to evaluate this…

WednesdayMar 17, 2021 1:03 pm

QualityStocksNewsBreaks – Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) Eye-Net Mobile Enters Strategic Commercial Agreement

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, today announced that its wholly owned subsidiary, Eye-Net Mobile Ltd., has signed a commercial cooperation agreement with SaverOne 2014 Ltd. (TASE: SAVR), a leader in providing an effective solution to combat cell phone distracted driving. According to the update, Eye-Net will integrate its Eye-Net(TM) Protect solution in SaverOne’s product designed to prevent the use of texting applications by the driver while the vehicle is in motion. The integration is subject to certain tests and criteria to be determined by the parties. “Eye-Net is expanding its presence in…

WednesdayMar 17, 2021 12:25 pm

QualityStocksNewsBreaks – Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Releases Annual, Q4 Financial Results

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) has released its financial numbers for the three- and twelve-month periods ended Dec. 31, 2020. Fourth-quarter financial and operational highlights of the report include a 41% increase in revenues from Q4 2019 ($9 million this quarter compared to $6.4 million in 2019); a gross profit increase of 37%, from a loss in Q4 2019 to $1.6 million in Q4 2020; an increase in silver production from 259,282 ounces in Q4 2019 to 355,581 in Q4 2020, resulting in the company’s strongest quarter of silver production since 2014. Fiscal year 2020 highlights included…

WednesdayMar 17, 2021 11:35 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved…

Site Search

Company Search

Category: QualityStocksNewsBreaks